Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: neuroscience – Page 291

Light-induced gene therapy disables cancer cells’ mitochondria

Researchers are shining a light on cancer cells’ energy centers—literally—to damage these power sources and trigger widespread cancer cell death. In a new study, scientists combined strategies to deliver energy-disrupting gene therapy using nanoparticles manufactured to zero in only on cancer cells. Experiments showed the targeted therapy is effective at shrinking glioblastoma brain tumors and aggressive breast cancer tumors in mice.

The research team overcame a significant challenge to break up structures inside these cellular energy centers, called mitochondria, with a technique that induces light-activated electrical currents inside the cell. They named the technology mLumiOpto.

“We disrupt the membrane, so mitochondria cannot work functionally to produce energy or work as a signaling hub. This causes programmed followed by DNA damage—our investigations showed these two mechanisms are involved and kill the ,” said co-lead author Lufang Zhou, professor of biomedical engineering and surgery at The Ohio State University. “This is how the technology works by design.”

Molecular motors put significant twists to DNA loops

Astrocytes are star-shaped glial cells in the central nervous system that support neuronal function, maintain the blood-brain barrier, and contribute to brain repair and homeostasis. The evolution of these cells throughout the progression of Alzheimer’s disease (AD) is still poorly understood, particularly when compared to that of neurons and other cell types.

Researchers at Massachusetts General Hospital, the Massachusetts Alzheimer’s Disease Research Center, Harvard Medical School and Abbvie Inc. set out to fill this gap in the literature.

Their paper, published in Nature Neuroscience, provides one of the most detailed accounts to date of how different astrocyte subclusters respond to AD across different brain regions and disease stages, providing valuable insights into the cellular dynamics of the disease.

Breakthrough Study: Natural Compound Could Counter Opioid Addiction Without Sacrificing Pain Relief

Boosting the endocannabinoid 2-AG in the brain can counteract opioid addiction while preserving their pain relief, a Weill Cornell Medicine study finds. This approach, tested in mice using the chemical JZL184, may lead to safer treatments for pain management.

The natural enhancement of chemicals produced by the body, known as endocannabinoids, may mitigate the addictive properties of opioids like morphine and oxycodone while preserving their pain-relieving effects, according to researchers from Weill Cornell Medicine in collaboration with The Center for Youth Mental Health at NewYork-Presbyterian. Endocannabinoids interact with cannabinoid receptors found throughout the body, which play a role in regulating functions such as learning and memory, emotions, sleep, immune response, and appetite.

Opioids prescribed to control pain can become addictive because they not only dull pain, but also produce a sense of euphoria. The preclinical study, published recently in the journal Science Advances, may lead to a new type of therapeutic that could be taken with an opioid regimen to only reduce the reward aspect of opioids.

Scientists Discover Genetic Changes Linked to Autism, Schizophrenia

The Tbx1 gene influences brain volume and social behavior in autism and schizophrenia, with its deficiency linked to amygdala shrinkage and impaired social incentive evaluation.

A study published in Molecular Psychiatry has linked changes in brain volume to differences in social behavior associated with psychiatric conditions like autism spectrum disorder and schizophrenia.

The research, led by Noboru Hiroi, Ph.D., a professor in the Department of Pharmacology at the Joe R. and Teresa Lozano Long School of Medicine at The University of Texas Health Science Center at San Antonio (UT Health San Antonio), revealed that a deficiency in a specific gene was connected to social behavior differences in mice. These behavioral differences are similar to those often observed in psychiatric disorders.

A New Era in Amphibian Biology: Scientists Use Viruses To Study Frog Nervous System Development

Researchers have developed a method using viruses to track neuronal development in frogs, shedding light on the evolution of vertebrate nervous systems and offering comparative insights with mammals.

Although viruses are typically associated with illnesses, not all viruses are harmful or cause disease. Some are instrumental in therapeutic treatments and vaccinations. In scientific research, viruses are often used to infect certain cells, genetically modify them, or visualize neurons in the organism’s central nervous system (CNS)—the command center made up of the brain, spinal cord, and nerves.

The highlighting process has now been successfully applied to amphibians, which are crucial for understanding the brain and spinal cord of tetrapods—four-limbed animals, including humans. This has been shown in a new study by an international EDGE consortium jointly led by the Sweeney Lab at the Institute of Science and Technology Austria (ISTA) and the Tosches Lab at Columbia University.

Astronomers Just Found Possibly The Largest Rotating Structures in The Universe

Scientists have discovered that cosmic filaments, the largest known structures in the universe, are rotating. These massive, twisting filaments of dark matter and galaxies stretch across hundreds of millions of light-years and play a crucial role in channeling matter to galaxy clusters. The finding challenges existing theories, as it was previously believed that rotation could not occur on such large scales. The research was confirmed through both computer simulations and real-world data, and it opens up new questions about how these giant structures acquire their spin.

After reading the article, a Reddit user named Kane gained more than 100 upvotes with this comment: “What if galaxy clusters are like neuron and glial clusters in a brain. And dark matter is basically the equivalent of a synapse. It connects galaxies and matter together and is responsible for sending quantum information back and forth like a signal chain.”

The future of neuroscience could be wireless

Though Elon Musk’s Neuralink put wireless brain implants in the spotlight — in early 2024, Musk announced his company’s first implant was successful — the research and development of these devices has spanned decades. The BrainGate clinical trials have been underway for 20 years, and the consortium’s wireless implant marks the first time a person has used an implant with high bandwidth capabilities.

Wireless technologies are opening doors in neuroscience, enabling new capabilities in communication, treatment, and research. Because wireless implants can monitor the brain for long periods of time, they offer a unique opportunity to examine neural dynamics, increasing our understanding of the human mind. Their cord-free design also benefits people hoping to use these devices outside a research setting and improve their quality of life.

The first brain implant is credited to neurologist Phil Kennedy, who had the device surgically affixed to his brain. Today, wired implants are less invasive and widely used. They can help prevent seizures, manage OCD symptoms, and treat movement disorders.

Cannabis Use and Schizophrenia Genetics: Separate Routes to Psychosis Risk

Dr. Marta di Forti: “Our study indicates that daily users of high potency cannabis are at increased risk of developing psychosis independently from their polygenic risk score for schizophrenia.”

Is there a connection between cannabis use and developing psychosis? This is what a recent study published in Psychological Medicine hopes to address as an international team of researchers investigated how frequent cannabis use combined with a genetic predisposition for schizophrenia could lead to developing psychosis later in life. This study holds the potential to help researchers, medical professionals, and the public better understand how to identify the signs of psychosis in cannabis users and take necessary steps to address them as soon as possible.

For the study, the researchers conducted an observational study by obtaining data records of almost 150,000 individuals registered in United Kingdom and European Union medical databanks, one of which was the European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI), to examine records regarding patients who self-reported use and psychosis diagnoses. In the end, the researchers discovered a connection between individuals who self-reported lifetime frequent cannabis use and psychosis diagnoses, specifically regarding high potency cannabis which contains 10 percent or greater Delta-9 tetrahydrocannabinol (THC).

“These are important findings at a time of increasing use and potency of cannabis worldwide,” said Dr. Marta di Forti, who is a Professor of Drug use, Genetics, and Psychosis at King’s College London and a co-author on the study. “Our study indicates that daily users of high potency cannabis are at increased risk of developing psychosis independently from their polygenic risk score for schizophrenia. Nevertheless, the polygenic risk score for schizophrenia might, in the near future, become useful to identify those at risk for psychosis among less frequent users to enable early preventative measures to be put in place.”

/* */